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background: There is a paucity of data on the use of induction immunosuppression in patients with active infections undergoing orthotopic heart 
transplantation (OHT). We hypothesized that induction immunosuppression in patients with ventricular assist device (VAD) undergoing OHT with 
localized active driveline infection (DLI) does not lead to worse outcomes.
Methods: We retrospectively analyzed our database for bridge-to-transplant VAD patients who underwent OHT. Patients were stratified into those 
with and without active DLI at the time of OHT and followed till death or at least 30 months after OHT. Post-transplant length of stay (LOS), mortality 
and development of infectious complications were compared between the two groups.
results: 38 patients (30 males) with mean age of 57.5 years with VAD underwent OHT during the study period. 12 had active DLI and 26 did not 
have DLI. Mean follow up was 46.4 ± 23.1 months. There was no difference in the post-transplant LOS, type of induction agent used, post-operative 
renal function or mortality between the two groups. There was no significant difference in development of any infection either in the first month 
or during entire follow up between the two groups (Table). None of the patients in the DLI group had infections attributable to the same organism 
responsible for pre-transplant DLI.
conclusion: In patients with active DLI, induction immunosuppression after OHT did not increase post-transplant LOS, infections or mortality after 
at least 30 months of follow up.
Characteristics of patients with and without driveline infections who had heart transplantation
Variable
Patients without driveline 
infection at the time of OHT 
(N= 26)
Patients with active driveline 
infection at the time of OHT (N=12)
P value
Mean age (years) 60 ± 13.2 52.03 ± 12.4 NS
Male gender 21 (81%) 9 (75%) NS
Caucasian race 22 (84%) 8 (66%) NS
Body Mass Index (kg/m2) 27 ± 3.4 29.6 ± 10.8 NS
Duration of LVAD support prior to transplantation (days) 220 ± 192.3 389.2 ± 180 0.02
Post Transplant Length of Stay (days) 17.2 ± 13.7 16.3 ± 5.4 NS
Development of infectious complication in first month post 
transplant
6 (23%) 3 (25%) NS
Development of any infection during follow up 23 (89%) 11 (92%) NS
Number of deaths 6 (23%) 2 (17%) NS
